TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company's commitment to advancing treatments for neurological disorders.
Howard Weisman, CEO of PaxMedica, affirmed, "Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for anti-purinergic therapies to address the core symptoms of autism spectrum disorder (ASD)."
The company is preparing to file a New Drug Application (NDA) with the FDA for the use of suramin in treating Human African Trypanosomiasis (HAT) as it has previously reported. Suramin has been recognized for nearly a century as a standard treatment for HAT in East Africa.
In April 2024, PaxMedica responded to an urgent request from Malawi for an emergency release of suramin, underscoring the company's commitment to addressing global health crises.
"We are not just continuing; we are intensifying our efforts to achieve significant milestones for these programs by the end of this year," Weisman added. "We are on track to submit an NDA for PAX-101, and potentially secure an FDA Priority Review Voucher if approved."
This proactive approach illustrates PaxMedica's dedication to advancing healthcare solutions globally.
紐約塔裏敦,2024年5月7日(GLOBE NEWSWIRE)——通過IBN——專注於推進神經系統疾病治療的生物製藥公司PaxMedica, Inc.(場外交易代碼:PXMD)根據其從納斯達克股票市場過渡的情況提供了公司最新情況,強調這一變化不會影響該公司推進神經系統疾病治療的承諾。
PaxMedica 首席執行官霍華德·韋斯曼申明:“我們在 PAX-101 保密協議提交方面取得進展的決心沒有受到影響,我們對進一步探索抗嘌呤能療法解決自閉症譜系障礙 (ASD) 核心症狀潛力的臨床項目承諾也沒有受到影響。”
正如其先前報道的那樣,該公司正準備向美國食品藥品管理局提交新藥申請(NDA),以使用舒拉明治療非洲人類錐蟲病(HAT)。近一個世紀以來,舒拉明一直被公認爲東非HAT的標準治療方法。
2024年4月,PaxMedica回應了馬拉維提出的緊急釋放舒拉明的緊急請求,這突顯了該公司對解決全球健康危機的承諾。
韋斯曼補充說:“我們不僅在繼續;我們還在加緊努力,爭取在今年年底之前實現這些計劃的重大里程碑。”“我們有望提交 PAX-101 的保密協議,如果獲得批准,我們有可能獲得美國食品藥品管理局的優先審查憑證。”
這種積極的方法表明了PaxMedica致力於在全球範圍內推進醫療保健解決方案的決心。